Premium
The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta‐analysis and trial sequential analysis
Author(s) -
Hristovska A.M.,
Duch P.,
Allingstrup M.,
Afshari A.
Publication year - 2018
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/anae.14160
Subject(s) - sugammadex , neostigmine , medicine , neuromuscular blockade , anesthesia , adverse effect , neuromuscular monitoring , rocuronium , propofol
Summary We compared the efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. Our outcomes were: recovery time from second twitch to train‐of‐four ratio > 0.9; recovery time from post‐tetanic count 1–5 to train‐of‐four ratio > 0.9; and risk of composite adverse and serious adverse events. We searched for randomised clinical trials irrespective of publication status and date, blinding status, outcomes reported or language. We included 41 studies with 4206 participants. Time to reversal of neuromuscular blockade from second twitch to a train‐of‐four ratio > 0.9 was 2.0 min with sugammadex 2 mg.kg −1 and 12.9 min with neostigmine 0.05 mg.kg −1 , with a mean difference (MD) (95%CI)) of 10.2 (8.5–12.0) (I 2 = 84%, 10 studies, n = 835, Grades of Recommendation, Assessment, Development and Evaluation (GRADE): moderate quality). Time to reversal of neuromuscular blockade from a post‐tetanic count of 1–5 to a train‐of‐four ratio > 0.9 was 2.9 min with sugammadex 4 mg.kg −1 and 48.8 min with neostigmine 0.07 mg.kg −1 , with a MD (95%CI) of 45.8 (39.4–52.2) (I 2 = 0%, 2 studies, n = 114, GRADE : low quality). There were significantly fewer composite adverse events in the sugammadex group compared with neostigmine, with a risk ratio (95%CI) of 0.60 (0.49–0.74) (I 2 = 40%, 28 studies, n = 2298, number needed to treat (NNT): 8, GRADE : moderate quality). Specifically, the risk of bradycardia ( RR (95%CI) 0.16 (0.07–0.34), n = 1218, NNT: 14, GRADE : moderate quality), postoperative nausea and vomiting ( RR (95%CI) 0.52 (0.28–0.97), n = 389, NNT: 16, GRADE : low quality) and overall signs of postoperative residual paralysis ( RR (95%CI) 0.40 (0.28–0.57), n = 1474, NNT: 13, GRADE : moderate quality) were all reduced. There was no significant difference regarding the risk of serious adverse events ( RR 0.54, 95%CI 0.13–2.25, I 2 = 0%, n = 959, GRADE : low quality). Sugammadex reverses neuromuscular blockade more rapidly than neostigmine and is associated with fewer adverse events.